Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Long-term high-intensity interval training may reduce the risk for the decline of kidney function in older adults, a study ...

By: Dr. Suresh D.R., Chief of Laboratory - Centralab Metropolis, Karnataka, and Regional COL - Andhra Pradesh and Telangana, ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Weight fluctuation was associated with a greater risk for diabetic kidney disease progression among individuals with type 1 diabetes.

Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March ...